Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan.

Autor:	Furukawa K; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Arii J; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Nishimura M; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Tjan LH; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Lystia Poetranto A; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Ren Z; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Aktar S; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Huang JR; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Sutandhio S; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Kurahashi Y; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Nishino A; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Shigekuni S; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Takeda Y; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan., Uto K; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan., Matsui K; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan., Sato I; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan., Inui Y; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan., Endo K; Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan., Kosaka Y; Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan., Oota T; Hyogo Prefecture Health Promotion Association, Kobe, Japan., Saegusa J; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan., Mori Y; Division of Clinical Virology, Center for Infectious Disease, Kobe University Graduate School of Medicine, Kobe, Japan.
Jazyk:	angličtina
Zdroj:	JMA journal [JMA J] 2021 Jan 29; Vol. 4 (1), pp. 41-49. Date of Electronic Publication: 2021 Jan 14.
DOI:	10.31662/jmaj.2020-0094
Abstrakt:	Introduction: The coronavirus disease 2019 (COVID-19) pandemic is spreading rapidly all over the world. The Japanese government lifted the state of emergency, announced in April 2020, on May 25, but there are still sporadic clusters. Asymptomatic patients who can transmit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause some of these clusters. It is thus urgent to investigate the seroprevalence of antibodies against SARS-CoV-2 and their neutralizing activity. We conducted a cross-sectional study of >10,000 samples at hospitals in Hyogo Prefecture, Japan. Methods: Between August 6 and October 1, 2020, we collected samples of residual blood from the patients who visited or were admitted to five hospitals and a foundation in Hyogo. We tested the samples for antibodies against SARS-CoV-2 by electrochemiluminescence immunoassay (ECLIA) and chemiluminescent enzyme immunoassay (CLEIA). Sera that were positive by ECLIA or CLEIA were analyzed by an immunochromatographic (IC) test and neutralizing activity assay. Results: We tested 10,377 samples from patients aged between 0 and 99 years old; 27 cases (0.26%) were positive on the ECLIA, and 51 cases (0.49%) were positive on CLEIA. In the 14 cases that tested positive on both ECLIA and CLEIA, the positive rates on the IC test and for neutralizing activity were high (85% and 92%, respectively). In 50 cases (0.48%) that were positive by either ECLIA or CLEIA, the corresponding rates were low (20% and 6%, respectively). The positive rate of neutralizing antibody was 0.15%. Conclusions: These results indicate that most Hyogo Prefecture residents still do not have antibodies and should avoid the risk of incurring a SARS-CoV-2 infection. Two or more antibody tests should be required for seroepidemiological studies of the antibody for SARS-CoV-2, and a neutralizing activity assay is also essential. Competing Interests: Yasuko Mori received the reagents for 5,000 samples used here from Roche as a collaboration of this research. (Copyright © Japan Medical Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu